Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro board director Lynne Fahey McGrath dies at age not stated, July 20, 2026

Neutral Impact 2 of 5 leadership Written later

Alzamend Neuro, Inc. disclosed that director Lynne Fahey McGrath passed away on July 20, 2026. She had served on the Board since the company's June 2021 initial public offering, and Chairman William B. Horne called her passing sudden.

Key points

  • Lynne Fahey McGrath, M.P.H., Ph.D., a director, died July 20, 2026
  • She had served on the Board since the company's initial public offering in June 2021
  • The filing does not state any board replacement or change to committee roles

The filing

CompanyAlzamend Neuro, Inc. (ALZN)
Form8-K, current report
Filed with the SECJul 21, 2026, 4:30 PM ET
Accession number0001214659-26-008772

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.